The National Institute for Health and Care Excellence (NICE) has requested further evidence on Amgen’s Blincyto (blinatumomab) for the treatment of adults with acute lymphoblastic leukaemia.

The committee concluded that Blincyto has significant clinical benefits, but that further evidence on cost-effectiveness is required to assess its plausibility for NHS funding. NICE has requested further clarification from the company for the second committee meeting in April.

Read the full article by Anna Smith here.